Amnovis acquires Westconn's additive activities, establishes US orthopedics hub in Indiana

Belgian metal AM contract manufacturer Amnovis has crossed the Atlantic, acquiring the additive manufacturing activities of Westconn Precision Technologies and establishing a US operational entity in North Webster, Indiana. The new site sits squarely within the Warsaw orthopedics ecosystem, the global hub for implant and instrument manufacturing. Amnovis is building what it describes as a mirror site of its Belgian headquarters — same equipment strategy, same quality management system, same digital workflows — to offer customers globally deployable manufacturing capacity with consistent validation across two continents. Chris Cook has been appointed General Manager of US Operations, while Jake Marasco, formerly of Westconn, will handle account management and business development in North America. This marks Amnovis' first acquisition since its founding in June 2020.

This acquisition fits the pattern of targeted geographic expansion by specialized medical AM service bureaus seeking to embed themselves within high-value, qualification-intensive supply chains. Amnovis is not opening a generic satellite office; it is replicating its entire quality and process-control infrastructure in the heart of the US orthopedics market. The Warsaw, Indiana cluster is home to major orthopedic OEMs including Zimmer Biomet, DePuy Synthes, and Medtronic's spinal division. By acquiring Westconn's additive activities — which bring hybrid manufacturing expertise and existing customer relationships — Amnovis gains immediate market access and talent rather than starting from scratch. The move reflects the medical-dental vertical's demand for validated, dual-source production capacity, a requirement that becomes more pressing as regulatory bodies scrutinize supply chain resilience. Amnovis' strategy mirrors that of other European medical AM specialists who have established US footholds to serve FDA-regulated customers without transatlantic shipping delays or qualification duplication.

For Amnovis, the execution challenge is now about maintaining process equivalence between two sites while navigating the specific regulatory and customer-relationship nuances of the US orthopedic market. The company's LPBF expertise in titanium and cobalt-chrome alloys for spinal and orthopedic implants is directly applicable, but the mirror-site concept only delivers value if customers trust that the Indiana facility can replicate Belgian quality metrics from day one. The appointment of local leadership with hybrid manufacturing experience is a pragmatic step; the real test will be how quickly the new site achieves its first customer qualification audits.